Sanofi 'Selecta's Early Stage Immunotherapy in $900M Deal
By Marie Powers
Thursday, November 29, 2012
Nanomedicine specialist Selecta Biosciences Inc., which has moved with rapid-fire speed over the past two years, landed a potential $900 million deal with Sanofi SA to discover targeted, antigen-specific immunotherapies for food allergies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.